World Journal of Surgery

, Volume 31, Issue 5, pp 879–887 | Cite as

TNM Classification of Thyroid Carcinoma

Article

Abstract

Background

The understanding of biology of well-differentiated thyroid cancer has improved in the last two decades with the detailed understanding of prognostic factors and risk group stratification. The risk groups are crucial in the management of thyroid cancer and overall prognosis.

TNM Staging System

The TNM staging system has been used in all human cancers, and it adheres to the biology of tumors. The data in thyroid cancer comes from retrospective studies, as there are no prospective randomized trials. The most recent TNM staging system was revised and published (6th edition) in 2002. The major attributes of the staging system include: age as the most important prognostic factor, and age is included in the staging system, below and above the age of 45; T1 tumors are considered to be those below 2 cm; T3 tumors include minor extrathyroidal extension invading the strap muscles; T4 tumors includes T4a and T4b, T4a being operable tumors; all anaplastic cancers are T4, although operable anaplastic thyroid cancers are considered to be T4a.

Conclusion

These changes in the TNM system are consistent with our current philosophy in the overall management of thyroid cancer and adjuvant therapy. The N staging system includes N1a and N1b—N1a being level VI lymph nodes, while N1b includes level IV and superior mediastinal and contralateral neck nodes. The TNM staging system helps reporting our data and comparing results in different parts of the world. However, there is no level I evidence in thyroid cancer.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Denoix PF. Tumor, Node and Metastasis (TNM). Bull Inst Nat Hyg (Paris) 1944;1:69Google Scholar
  2. 2.
    Sobin LH. TNM: evolution and relation to other prognostic factors. Semin Surg Oncol 2003;21:3–7CrossRefPubMedGoogle Scholar
  3. 3.
    Gospodaroqicz MK, Miller D, Groome PA, et al. The process for continuous improvement of the TNM classification. Cancer 2004;100:1–5CrossRefGoogle Scholar
  4. 4.
    In: Greene FL, Compton CC, Fritz AG, Shah JP, Winchester DP (2006) AJCC Cancer Staging Atlas Springer New YorkGoogle Scholar
  5. 5.
    Hughes CJ, Shaha AR, Shah JP, et al. Impact of lymph node metastasis in differentiated carcinoma of the thyroid—a matched pair analysis. Head Neck 1996;18:127–132CrossRefPubMedGoogle Scholar
  6. 6.
    Sugitani I, Kasai N, Fujimoto Y, et al. A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery 2004;135(2):139–148CrossRefPubMedGoogle Scholar
  7. 7.
    Shaha AR. Controversies in the management of thyroid nodule. Laryngoscope 2000;110(2 Pt 1):183–193CrossRefPubMedGoogle Scholar
  8. 8.
    Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the US, 1985–1995. Cancer 1998;83:2638–2648CrossRefPubMedGoogle Scholar
  9. 9.
    Hay ID, Grant CS, Taylor WF, et al. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 1987;102:1088–1095PubMedGoogle Scholar
  10. 10.
    Hay ID, Bergstralh EJ, Goellner JR, et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993;114:947–953Google Scholar
  11. 11.
    Shaha AR, Loree TR, Shah JP. Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery 1995;118:1131–1138CrossRefPubMedGoogle Scholar
  12. 12.
    Byar DP, Green SB, Dor P, et al. A prognostic index for thyroid carcinoma: a study of the EORTC Thyroid Cancer Cooperative Group. Eur J Cancer 1979;15:1033–1041PubMedGoogle Scholar
  13. 13.
    Cady B. Our AMES is true: how an old concept still hits the mark, or risk group assignment points the arrow to rational therapy selection in differentiated thyroid cancer. Am J Surg 1997;174:462–468CrossRefPubMedGoogle Scholar
  14. 14.
    Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 1988;104:947–953PubMedGoogle Scholar
  15. 15.
    Pasieka JL, Zedenius J, Auer G, et al. Addition of nuclear DNA content to the AMES risk-group classification for papillary thyroid cancer. Surgery 1992;112:1154–1160PubMedGoogle Scholar
  16. 16.
    Schindler A, et al. Prognostic factors in papillary carcinoma of the thyroid. Cancer 1991;68:324–330CrossRefPubMedGoogle Scholar
  17. 17.
    Simpson WJ, et al. Papillary and follicular thyroid cancer: prognostic factors in 1578 patients. Am J Med 1987;83:479–488CrossRefPubMedGoogle Scholar
  18. 18.
    Tubiana M, et al. Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 1985;55:794–804CrossRefPubMedGoogle Scholar
  19. 19.
    Shaha AR, Shah JP, Loree TR. Low-risk differentiated thyroid cancer: the need for selective treatment. Ann Surg Oncol 1997;4:328–333CrossRefPubMedGoogle Scholar
  20. 20.
    Clark OH. Total thyroidectomy: the treatment of choice for patients with differentiated thyroid cancer. Ann Surg 1982;196:361–370CrossRefPubMedGoogle Scholar
  21. 21.
    Coburn MC, Wanebo HJ. Prognostic factors and management considerations in patients with cervical metastases of thyroid cancer. Am J Surg 1992;164:671–676CrossRefPubMedGoogle Scholar
  22. 22.
    Shah JP, et al. Prognostic factors in differentiated carcinoma of the thyroid gland. Am J Surg 1992;164:658–661CrossRefPubMedGoogle Scholar
  23. 23.
    Cunningham MP, et al. Survival discriminants for differentiated thyroid cancer. Am J Surg 1990;16:344–347CrossRefGoogle Scholar
  24. 24.
    Noguchi M, et al. Multivariate study of prognostic factors of differentiated thyroid carcinoma: The significance of histologic subtype. Int Surg 1993;78:10–15PubMedGoogle Scholar
  25. 25.
    Mazzaferri EL, Jhiang SM. Long-term of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418–428CrossRefGoogle Scholar
  26. 26.
    Mazzaferri EL. Review. Papillary thyroid carcinoma: factors influencing prognosis and current therapy. Semin Oncol 1987;14:315–332PubMedGoogle Scholar
  27. 27.
    Cady B. Staging in thyroid carcinoma. Cancer 1998;83:844–847CrossRefPubMedGoogle Scholar
  28. 28.
    Sherman SI, Brierley JD, Sperling M, et al. Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 1998;83:1012–1021CrossRefPubMedGoogle Scholar
  29. 29.
    Gilliland FD, Hunt WC, Morris DM, et al. Prognostic factors for thyroid carcinoma: a population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program, 1973–1991. Cancer 1997;79:564–573CrossRefPubMedGoogle Scholar
  30. 30.
    Anderson PE, et al. Differentiated carcinoma of the thyroid with extrathyroidal extension. Am J Surg 1995;170:467–470CrossRefGoogle Scholar
  31. 31.
    Czaja JM, McCaffrey TV. The surgical management of laryngotracheal invasion by well-differentiated papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg 1997;123:484–490PubMedGoogle Scholar
  32. 32.
    Grillo HC, Zannini P. Resectional management of airway invasion by thyroid carcinoma. Ann Thorac Surg 1986;42:287–298PubMedCrossRefGoogle Scholar
  33. 33.
    McCaffrey TV, Bergstralh EJ, Hay ID. Locally invasive papillary thyroid carcinoma:1940–1990. Head Neck 1994;16:165–172CrossRefPubMedGoogle Scholar
  34. 34.
    Passler C, Scheuba C, Asari R, et al. Importance of tumour size in papillary and follicular thyroid cancer. Br J Surg 2005;92(2):184–189CrossRefPubMedGoogle Scholar
  35. 35.
    Machens A, Holzhausen HJ, Dralle H. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer 2005;103(11):2269–2273CrossRefPubMedGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2007

Authors and Affiliations

  1. 1.Head and Neck ServiceMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  2. 2.Cornell University Medical CenterNew YorkUSA

Personalised recommendations